Vivesto AB · OMXSTO:VIVE
Vivesto AB — Oasmia Pharmaceutical — Q3 2020 Earnings Presentation
15 slides from Vivesto AB's earnings presentation, Feb 19, 2021
Slide 1: Q3 and Year End Results (1 May – 31 Dec 2020)
Q3 AND YEAR END RESULTS (1 MAY – 31 DEC 2020) F.R. Martelet, M.D., CEO 19 February 2021 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Today's speakers
Today’s speakers FRANCOIS MARTELET, M.D. ROBERT MAIORANA Chief Executive Officer Acting Chief Financial Officer/Finance Manager 3
Slide 4: 2020 – a year of delivery and transformation
2020 – a year of delivery and transformation Clearly defined strategy for growth 2021 onwards Maximizing Apealea® Opportunity to build a sustainable, profitable specialty pharma company Expanding the pipeline through in-house R&D, M&A, and in-licensing of clinical assets Focusing resources Building
Slide 5: A clearly defined strategy: key achievements May – December 2020
A clearly defined strategy: key achievements May – December 2020 1 2 3 4 Execute on Apealea® Enhancement & Clinical development In- & out-licensing, global partnership partnering of of Docetaxel partnering & M&A with Elevar technology platforms micellar in oncology • US regulatory pathway • Work und
Slide 6: Q3 and Year end Financial Highlights
Q3 and Year end Financial Highlights 1,2 • Cash and cash equivalents & short-term investments TSEK 287,405 (325,658) • Consolidated net sales TSEK 482 (565) • Operating profit/loss TSEK -131,493 (-117,256) • Cash burn to reduce over the next two years to 10-12 MSEK per month • Net profit/loss after
Slide 7: Maximizing Apealea® - global commercialization progressing well
Maximizing Apealea® - global commercialization progressing well Nordic states Peak sales • Oasmia commercializing estimates ~$275m - $282m (ovarian Europe (excluding Nordics) cancer1) USA • Commercialization agreement signed • Pathway to commercialization identified between Elevar Therapeutics and a
Slide 8: Expanding the portfolio and pipeline with a focus on oncology
Expanding the portfolio and pipeline with a focus on oncology Registration / Commercial Product Indication Pre-clinical Phase 1 Phase 2 Phase 3 approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer USA Paclical® (paclitaxel)1 Ovarian cancer EU / EEA Docetaxel Prostate cancer Glo
Slide 9: Improving and expanding the use of our technologies
Improving and expanding the use of our technologies Project Objective Discovery Feasibility Development Validation Launch Solubilization platform XR-17™ Out licensing and sales Next generation of XR-18 XR-17 Target 2023 Out licensing and sales Solubilization platform XR-19 – dual encapsulation Targe
Slide 10: Docetaxel micellar – initiating phase 1b to target prostate cancer
Docetaxel micellar – initiating phase 1b to target prostate cancer • Docetaxel approved for wide 1 in 7 range of solid malignancies men will be diagnosed with • Standard of care for advanced prostate cancer prostate cancer • Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel wit
Slide 11: In-licensing opportunities mainly in oncology
In-licensing opportunities mainly in oncology • We’re looking to in-license oncology products from pre-clinical up to late Phase 3 development Registration / Pre-clinical Phase 1 Phase 2 Phase 3 approval Marketed • We’re also pursuing collaborations to support partners’ R&D and overcome solubility c
Slide 12: Focusing resources to invest in high growth opportunities
Focusing resources to invest in high growth opportunities Ongoing process to partner Animal Health assets Strategic review to identify cost savings and synergies Paccal Vet • Annualized cost savings of more than SEK 100m delivered • XR-17™-based formulation of paclitaxel for mastocytoma in dogs • Re
Slide 13: Building a new leadership team for success
Building a new leadership team for success FRANCOIS MARTELET, FREDRIK JÄRRSTEN* DR HEIDI B. RAMSTAD REINHARD KOENIG, M.D. ELIN TRAMPE, M.A. PETER SELIN, B.Sc. M.D., Master’s Degree Business Chief Finance Officer M.D. Acting Chief Scientific Chief Technical Officer Chief Business Officer Chief Execut
Slide 14: Looking ahead – multiple catalysts to drive value in 2021
Looking ahead – multiple catalysts to drive value in 2021 Potential near- and mid-term value drivers • Elevar partnering for Apealea® in key territories, milestone payments and royalties • XR-18 platform development and XR-19 lab proof of concept • SAKK docetaxel micellar Phase 1b preparations well
Slide 15: Thank you!
Thank you! Oasmia Pharmaceutical AB (STO: OASM) +46 018-50 54 40 www.linkedin.com/comp Vallongatan 1 any/oasmia- 752 28 Uppsala [email protected] pharmaceutical-ab Sweden www.oasmia.com www.twitter.com/Oasmia
Oasmia Pharmaceutical — Q3 2020 Earnings Presentation on 6ix